Ratings Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
21.19 ^USD	+1.53%		-0.47%	-41.69%

03-04	Prothena Names David Ford as Chief People Officer	MT
03-04	Prothena Appoints David Ford to Newly Created Chief People Officer	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PROTHENA CORPORATION PLC	-41.69%	1.14B	C-
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B	B+
ARGENX SE	+1.98%	22.18B	B
BIONTECH SE	-16.67%	21.2B	B+
GENMAB A/S	-9.35%	18.31B	A-
WUXI APPTEC CO., LTD.	-38.74%	17.38B	A-
BEIGENE, LTD.	-13.21%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B	C+
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes